WO2013082469A3 - Methods and compositions for treating infections - Google Patents

Methods and compositions for treating infections Download PDF

Info

Publication number
WO2013082469A3
WO2013082469A3 PCT/US2012/067360 US2012067360W WO2013082469A3 WO 2013082469 A3 WO2013082469 A3 WO 2013082469A3 US 2012067360 W US2012067360 W US 2012067360W WO 2013082469 A3 WO2013082469 A3 WO 2013082469A3
Authority
WO
WIPO (PCT)
Prior art keywords
contamination
apicomplexan
methods
infection
compositions
Prior art date
Application number
PCT/US2012/067360
Other languages
French (fr)
Other versions
WO2013082469A2 (en
Inventor
Christopher D. HUSTON
Kovi BESSOFF
Original Assignee
University Of Vermont And State Agricultural College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Vermont And State Agricultural College filed Critical University Of Vermont And State Agricultural College
Publication of WO2013082469A2 publication Critical patent/WO2013082469A2/en
Publication of WO2013082469A3 publication Critical patent/WO2013082469A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates, in part, to methods to identify compounds to treat an apicomplexan infection and/or reduce apicomplexan contamination, and to methods and compositions to treat apicomplexan infections and to reduce apicomplexan contamination. In some aspects the invention the apicomplexan infection or contamination is Cryptosporidium infection or contamination. In certain aspects the invention includes compositions useful to treat Cryptosporidium infection in a subject and/or to reduce Cryptosporidium contamination of a substrate such as a liquid or solid surface, object, or material.
PCT/US2012/067360 2011-12-02 2012-11-30 Methods and compositions for treating infections WO2013082469A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161566331P 2011-12-02 2011-12-02
US61/566,331 2011-12-02
US201261669822P 2012-07-10 2012-07-10
US61/669,822 2012-07-10

Publications (2)

Publication Number Publication Date
WO2013082469A2 WO2013082469A2 (en) 2013-06-06
WO2013082469A3 true WO2013082469A3 (en) 2013-09-26

Family

ID=48536239

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/067360 WO2013082469A2 (en) 2011-12-02 2012-11-30 Methods and compositions for treating infections

Country Status (1)

Country Link
WO (1) WO2013082469A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103705516B (en) * 2013-12-11 2016-01-06 武汉威立得生物医药有限公司 The application of chloroxine in the medicine preparing treatment or flu-prevention viral infection
CN104688728A (en) * 2015-02-05 2015-06-10 郑州点石生物技术有限公司 Application of lovastatin in preparation of drugs for resisting cryptosporidium parvum
US10363254B2 (en) 2015-03-31 2019-07-30 University Of Vermont And State Agricultural College Methods for treating cryptosporidiosis using triazolopyridazines
KR102431257B1 (en) 2016-04-11 2022-08-10 장피트 Methods of treatment of cholestatic and fibrotic diseases
IL262186B2 (en) * 2016-04-11 2023-10-01 Genfit Synergistic combinations of nitazoxanide (ntz) compounds and statins
CA3054103A1 (en) 2017-03-13 2018-09-20 Genfit Pharmaceutical compositions for combination therapy
CN108434128A (en) * 2018-04-08 2018-08-24 广州市汇鑫动物药业有限公司 Application of the Levobunolol Hydrochorid in preparing medicament for resisting Eimeria tenella

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030113822A1 (en) * 2001-05-22 2003-06-19 President And Fellows Of Harvard College For Inventors Westwood And Mitchison Identification of anti-protozoal agents
US20050148628A1 (en) * 2002-02-13 2005-07-07 Edgar Muller Pharmaceutical combination of artesunate and mefloquine for therapy of malaria
WO2011025969A1 (en) * 2009-08-27 2011-03-03 The U.S.A., As Represented By The Secretary, Dept. Of Health And Human Services Compounds that treat malaria and prevent malaria transmission
US20110086821A1 (en) * 2000-01-24 2011-04-14 Trustees Of Tufts College Tetracycline Compounds for Treatment of Cryptosporidium Parvum Related Disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110086821A1 (en) * 2000-01-24 2011-04-14 Trustees Of Tufts College Tetracycline Compounds for Treatment of Cryptosporidium Parvum Related Disorders
US20030113822A1 (en) * 2001-05-22 2003-06-19 President And Fellows Of Harvard College For Inventors Westwood And Mitchison Identification of anti-protozoal agents
US20050148628A1 (en) * 2002-02-13 2005-07-07 Edgar Muller Pharmaceutical combination of artesunate and mefloquine for therapy of malaria
WO2011025969A1 (en) * 2009-08-27 2011-03-03 The U.S.A., As Represented By The Secretary, Dept. Of Health And Human Services Compounds that treat malaria and prevent malaria transmission

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PRADINES ET AL.: "Atorvastatin is 10-fold more active in vitro than other statins against Plasmodium falciparum", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 51, no. 7, 2007, pages 2654 - 2655 *

Also Published As

Publication number Publication date
WO2013082469A2 (en) 2013-06-06

Similar Documents

Publication Publication Date Title
WO2013082469A3 (en) Methods and compositions for treating infections
WO2013122888A3 (en) Methods of treating bacterial infections
WO2012020214A3 (en) Anti-microbial metal organic framework
WO2012170807A3 (en) Anti-pseudomonas psl binding molecules and uses thereof
SG10201605697UA (en) Aqueous alkaline compositions and method for treating the surface of silicon substrates
TN2013000310A1 (en) Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections
SG11201406961PA (en) Cleaning agent for semiconductor substrates and method for processing semiconductor substrate surface
EA201400092A1 (en) COMPOSITION
BR112013026805A2 (en) polyorganosiloxanes or silanes for the treatment of lignocellulosic materials, compositions comprising at least one polysiloxane and / or silane; compositions comprising at least one polysiloxane and / or silane; process for treating lignocellulosic material; use of at least one polysiloxane and / or silane; lignocellulosic material, comprising at least one polysiloxane and / or silane
EP2580303A4 (en) Aqueous alkaline etching and cleaning composition and method for treating the surface of silicon substrates
EP2573801A4 (en) Etching solution, and method for processing surface of silicon substrate
WO2012017321A3 (en) Treatment for dyslipidemia
WO2012162580A3 (en) Anti-viral compounds
CA2836511C (en) Matriptase inhibitors and uses thereof against orthomyxoviridae infections
SG10201604412RA (en) Device for treating surfaces of wafer-shaped articles
WO2013022550A3 (en) Small molecule inhibitors of ebola and lassa fever viruses
WO2012020108A3 (en) Multimeric inhibitors of viral fusion and uses thereof
UA107346C2 (en) Use of nifuratel to treat infections caused by atopobium species
WO2012162578A3 (en) Anti-viral compounds
EP2736961A4 (en) Coating composition, method for coating surface of material using the same, and surface treated materials having the same
GB201107985D0 (en) Process
EP3006434A4 (en) Novel compound derived from plant of genus quamoclit and composition containing same as active ingredient for preventing or treating diabetes
WO2011028890A3 (en) Compositions and methods for treatment of neuropathic pain
PL2716684T3 (en) Compounds for the prophylaxis and treatment of the adhesion process
WO2012051251A8 (en) Methods of treating giardiasis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12854335

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12854335

Country of ref document: EP

Kind code of ref document: A2